Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.32 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.32 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.32 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7779967 | 0.73 | CA2 (0.38) | CA2CA9ACE2HSD11B1ABCC9 | |
| SCHEMBL7780123 | 0.71 | CA2 (0.36) | CA2CA9HSD11B1ABCC9ABCC8 | |
| SCHEMBL31568288 | 0.69 | PDE3B (0.36) | CA2CA9 | |
| SCHEMBL22226932 | 0.67 | CA9 (0.58) | CA2CA9ACE2HSD11B1ABCC9 | |
| SCHEMBL29700287 | 0.66 | CA2 (0.40) | CA2CA9ACE2ABCC9ABCC8 | |
| SCHEMBL17097221 | 0.63 | CA9 (0.58) | CA2CA9ACE2ABCC9ABCC8 | |
| SCHEMBL14397033 | 0.62 | CA12 (0.33) | CA2CA9 | |
| SCHEMBL12292087 | 0.62 | CA12 (0.33) | CA2CA9 | |
| SCHEMBL21527809 | 0.61 | CA2 (0.46) | CA2CA9ACE2ABCC9ABCC8 | |
| SCHEMBL29700002 | 0.61 | CA2 (0.32) | CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903221-B2 | Method for producing β-ketoenol esters | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-07 | — | — | US | disclosed |
| US-20030191318-A1 | Method for producing beta ketoenol esters | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | US | disclosed |
| EP-1311469-A1 | METHOD FOR PRODUCING BETA- KETOENOL ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016305-A1 | METHOD FOR PRODUCING β KETOENOL ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191318-A1 | Method for producing beta ketoenol esters | HSD17B7, AKR1B1, AKR1A1 | CA2 420/4885CA9 635/4885ACE2 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.